We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.52%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
51
Inspire Medical Systems
INSP
$1.82B
$66.3M 0.7%
320,188
+20,971
+7% +$4.46M
SWAV
52
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$63.1M 0.67%
484,564
+59,229
+14% +$7.1M
SILK
53
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$58.7M 0.62%
1,158,924
+786,034
+211% +$43.7M
BIO icon
54
Bio-Rad Laboratories Class A
BIO
$10.3B
$57.2M 0.61%
100,202
+35,797
+56% +$21.2M
CRL icon
55
Charles River Laboratories
CRL
$13.8B
$54.6M 0.58%
188,385
+45,367
+32% +$12.6M
BDTX icon
56
Black Diamond Therapeutics
BDTX
$122M
$54.4M 0.58%
2,243,000
+840,000
+60% +$22.7M
PACB icon
57
Pacific Biosciences
PACB
$420M
$53.9M 0.57%
1,617,505
-80,674
-5% -$2.82M
EPIX
58
DELISTED
ESSA Pharma
EPIX
$53M 0.56%
+1,825,814
New +$42.4M
TFX icon
59
Teleflex
TFX
$5.86B
$50.4M 0.53%
121,361
+3,583
+3% +$1.43M
RVMD icon
60
Revolution Medicines
RVMD
$45B
$48.9M 0.52%
1,065,770
+1,025,770
+2,564% +$46M
PEN icon
61
Penumbra
PEN
$12.7B
$48.7M 0.52%
179,875
+32,380
+22% +$8.36M
MOH icon
62
Molina Healthcare
MOH
$10.5B
$48M 0.51%
205,234
+5,546
+3% +$1.24M
TNDM icon
63
Tandem Diabetes Care
TNDM
$1.38B
$46.5M 0.49%
527,134
+141,950
+37% +$13.2M
TDOC icon
64
Teladoc Health
TDOC
$1.14B
$46.3M 0.49%
254,577
+44,225
+21% +$10.3M
GH icon
65
Guardant Health
GH
$21.7B
$46.2M 0.49%
302,866
+123,625
+69% +$18.7M
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
$46.1M 0.49%
114,000
+36,960
+48% +$17.9M
ABMD
67
DELISTED
Abiomed Inc
ABMD
$45.5M 0.48%
142,684
+35,127
+33% +$11.2M
BEAM icon
68
Beam Therapeutics
BEAM
$3.06B
$45.4M 0.48%
566,821
+170,000
+43% +$16.2M
ZBH icon
69
Zimmer Biomet
ZBH
$18.7B
$44.8M 0.47%
288,484
+36,380
+14% +$5.64M
IDXX icon
70
Idexx Laboratories
IDXX
$42.2B
$44.6M 0.47%
91,249
+13,164
+17% +$6.6M
AMGN icon
71
Amgen
AMGN
$236B
$43.9M 0.46%
176,440
-41,550
-19% -$9.91M
OMCL icon
72
Omnicell
OMCL
$1.57B
$42.6M 0.45%
327,919
+31,616
+11% +$4.05M
ABBV icon
73
AbbVie
ABBV
$453B
$41.6M 0.44%
384,100
+8,600
+2% +$920K
TXG icon
74
10x Genomics
TXG
$8.16B
$41.5M 0.44%
229,039
+63,916
+39% +$11M
GKOS icon
75
Glaukos
GKOS
$10.5B
$41.1M 0.43%
489,342
+40,010
+9% +$3.52M
1 2
3
4 5

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.